Table 1.
Baseline Demographics and Clinical Characteristics.
| PFS Population | OS Population | |||
|---|---|---|---|---|
| Characteristic | Cabozantinib (N=187) |
Everolimus (N=188) |
Cabozantinib (N=330) |
Everolimus (N=328) |
| Age – yr | ||||
| Median | 62 | 61 | 63 | 62 |
| Range | 36 – 83 | 31 – 84 | 32 – 86 | 31 – 84 |
| Sex – no. (%) | ||||
| Male | 142 (76) | 130 (69) | 253 (77) | 241 (73) |
| Female | 45 (24) | 57 (30) | 77 (23) | 86 (26) |
| Not reported | 0 | 1 (<1) | 0 | 1 (<1) |
| Geographic Region – no. (%) | ||||
| Europe | 83 (44) | 84 (45) | 167 (51) | 153 (47) |
| North America | 76 (41) | 64 (34) | 118 (36) | 122 (37) |
| Asia-Pacific | 25 (13) | 36 (19) | 39 (12) | 47 (14) |
| Latin America | 3 (2) | 4 (2) | 6 (2) | 6 (2) |
| Ethnic origin – no. (%) | ||||
| White | 157 (84) | 147 (78) | 269 (82) | 263 (80) |
| Asian | 12 (6) | 20 (11) | 21 (6) | 26 (8) |
| Black or African-American | 4 (2) | 2 (1) | 6 (2) | 3 (1) |
| Other | 10 (5) | 6 (3) | 19 (6) | 13 (4) |
| Not reported | 4 (2) | 12 (6) | 15 (5) | 22 (7) |
| Missing | 0 | 1 (<1) | 0 | 1 (<1) |
| ECOG performance status – no. (%) | ||||
| 0 | 129 (69) | 116 (62) | 226 (69) | 217 (66) |
| 1 | 58 (31) | 72 (38) | 104 (32) | 111 (34) |
| MSKCC risk group22 – no. (%) | ||||
| Favorable | 80 (43) | 83 (44) | 150 (45) | 150 (46) |
| Intermediate | 78 (42) | 75 (40) | 137 (42) | 135 (41) |
| Poor | 29 (16) | 30 (16) | 43 (13) | 43 (13) |
| Prior VEGFR TKIs – no. (%) | ||||
| 1 | 137 (73) | 136 (72) | 235 (71) | 229 (70) |
| ≥ 2 | 50 (27) | 52 (28) | 95 (29) | 99 (30) |
| Previous systemic therapy – no. (%) | ||||
| Sunitinib | 122 (65) | 121 (64) | 226 (69) | 224 (68) |
| Pazopanib | 89 (48) | 80 (43) | 149 (45) | 138 (42) |
| Axitinib | 28 (15) | 27 (14) | 52 (16) | 56 (17) |
| Sorafenib | 11 (6) | 19 (10) | 21 (6) | 33 (10) |
| Bevacizumab | 1 (<1) | 7 (4) | 5 (2) | 10 (3) |
| Interleukin 2 | 11 (6) | 13 (7) | 20 (6) | 31 (10) |
| Interferon-α | 6 (3) | 12 (6) | 21 (6) | 23 (7) |
| Nivolumab | 9 (5) | 11 (6) | 17 (5) | 14 (4) |
| Radiotherapy – no. (%) | 55 (29) | 59 (31) | 109 (33) | 107 (32) |
| Nephrectomy – no. (%) | 156 (83) | 154 (82) | 284 (86) | 280 (85) |
ECOG, Eastern Cooperative Oncology Group; MSKCC, Memorial Sloan-Kettering Cancer Center; PFS, Progression-free Survival; OS, Overall Survival; VEGFR TKI, Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor.